MDT

96.25

-0.26%↓

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

MDT

96.25

-0.26%↓

146.56

-0.77%↓

VEEV

228.6

-2.4%↓

HQY

84.77

+0.21%↑

PHR.US

16.55

-3.55%↓

Начало・Списък с акции・Vaxart Inc

Vaxart Inc

Отворен

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

Ключови измерители
By Trading Economics
Приходи	6.8M -8.1M
Продажби	33M 72M
EPS	-0.04
Марж на печалбата	-11.242
Служители	105
EBITDA	6.7M -5.4M

Дивиденти
By Dow Jones
Следващи печалби	19.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-116K 91M
Предишно отваряне	0
Предишно затваряне	0

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

0.4007 / 0.4252 Подкрепа & съпротива

Vaxart Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.01.2026 г., 23:54 ч. UTC

Пазарно говорене

CBA Could Underperform Again in 2026 -- Market Talk

12.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

12.01.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Edges Lower on Likely Technical Correction -- Market Talk

12.01.2026 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12.01.2026 г., 21:56 ч. UTC

Пазарно говорене

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

12.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Auto & Transport Roundup: Market Talk

12.01.2026 г., 21:18 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

12.01.2026 г., 21:18 ч. UTC

Пазарно говорене

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12.01.2026 г., 20:54 ч. UTC

Печалби

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12.01.2026 г., 20:48 ч. UTC

Пазарно говорене

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12.01.2026 г., 20:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12.01.2026 г., 20:18 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12.01.2026 г., 20:18 ч. UTC

Придобивния, сливания и поглъщания

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12.01.2026 г., 19:39 ч. UTC

Пазарно говорене

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12.01.2026 г., 19:36 ч. UTC

Пазарно говорене

Gold and Silver Set New Records on Fed Probe -- Market Talk

12.01.2026 г., 19:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.01.2026 г., 19:33 ч. UTC

Пазарно говорене

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12.01.2026 г., 19:24 ч. UTC

Придобивния, сливания и поглъщания

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12.01.2026 г., 19:22 ч. UTC

Придобивния, сливания и поглъщания

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12.01.2026 г., 18:21 ч. UTC

Придобивния, сливания и поглъщания

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12.01.2026 г., 18:20 ч. UTC

Придобивния, сливания и поглъщания

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12.01.2026 г., 18:19 ч. UTC

Пазарно говорене

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12.01.2026 г., 18:16 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12.01.2026 г., 18:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

12.01.2026 г., 18:09 ч. UTC

Пазарно говорене

Baidu's Outlook Bodes Well For Shares -- Market Talk

12.01.2026 г., 18:01 ч. UTC

Придобивния, сливания и поглъщания

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12.01.2026 г., 18:00 ч. UTC

Пазарно говорене

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Vaxart Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Vaxart Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.4007 / 0.4252Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.